Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly  Settings
SLNO Soleno Therapeutics, Inc. daily Stock Chart
SLNO [NASD]
Soleno Therapeutics, Inc.
Healthcare | Medical Laboratories & Research | USA
financial highlights | statements
Index- P/E22.28 EPS (ttm)0.09 Insider Own26.33% Shs Outstand10.78M Perf Week46.43%
Market Cap22.10M Forward P/E- EPS next Y-1.10 Insider Trans- Shs Float- Perf Month20.59%
Income-6.10M PEG- EPS next Q-0.29 Inst Own88.40% Short Float- Perf Quarter30.57%
Sales- P/S- EPS this Y95.10% Inst Trans186.21% Short Ratio0.04 Perf Half Y2.50%
Book/sh0.66 P/B3.11 EPS next Y-0.90% ROA-49.70% Target Price14.00 Perf Year10.81%
Cash/sh0.95 P/C2.17 EPS next 5Y- ROE-87.20% 52W Range1.11 - 5.07 Perf YTD19.88%
Dividend- P/FCF- EPS past 5Y48.90% ROI- 52W High-59.57% Beta3.24
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low84.68% ATR0.44
Employees12 Current Ratio4.60 Sales Q/Q- Oper. Margin- RSI (14)56.86 Volatility43.07% 16.55%
OptionableNo Debt/Eq0.00 EPS Q/Q58.20% Profit Margin- Rel Volume0.50 Prev Close2.28
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.54M Price2.05
Recom2.00 SMA2021.39% SMA5020.05% SMA200-0.80% Volume773,547 Change-10.09%
Feb-13-18Reiterated Maxim Group Buy $8 → $4
Mar-20-19 07:48AM  Soleno Therapeutics Inc (SLNO) Files 10-K for the Fiscal Year Ended on December 31, 2018 GuruFocus.com -10.09%
Mar-18-19 08:30AM  Soleno Therapeutics, Analyst Review and Pipeline Progress ACCESSWIRE
08:00AM  Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2018 Financial Results GlobeNewswire
Mar-15-19 04:05PM  Four Healthcare Stocks Picking Up Speed On Friday ACCESSWIRE +98.52%
03:00PM  Soleno Therapeutics News: Why SLNO Stock Is Skyrocketing Today InvestorPlace
07:39AM  The Daily Biotech Pulse: KaryoPharm's Selinexor Review Delayed, FDA Accepts Adamis Opioid Overdose Drug NDA Benzinga
Mar-14-19 05:32PM  Soleno Therapeutics Announces Positive Outcome from Planned Data Safety Monitoring Board Review of Phase III DESTINY PWS Clinical Trial of DCCR in Prader-Willi Syndrome Business Wire
Mar-11-19 04:05PM  Soleno Therapeutics to Participate in Two Upcoming Investor Conferences GlobeNewswire
Dec-19-18 04:01PM  Soleno Therapeutics Announces $16.5 Million Private Placement GlobeNewswire
Dec-12-18 06:47AM  Is Soleno Therapeutics, Inc.s (NASDAQ:SLNO) CEO Pay Justified? Simply Wall St. -8.14%
Nov-15-18 08:05AM  Soleno Therapeutics Presents Clinical Fat Loss Data on DCCR at the Obesity Society Meeting 2018 GlobeNewswire
08:00AM  Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Results GlobeNewswire
Oct-08-18 08:00AM  Soleno Therapeutics Presents Clinical Data on DCCR at 2018 Foundation for Prader-Willi Research Annual Conference GlobeNewswire -11.31%
Oct-01-18 08:00AM  Soleno Therapeutics Presents Clinical Data on DCCR at Late-Breaking Session of European Society for Paediatric Endocrinology GlobeNewswire +5.09%
Sep-19-18 08:00AM  Soleno Therapeutics to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease GlobeNewswire
Sep-17-18 08:00AM  Soleno Therapeutics to Present DCCR Clinical Data at Late Breaking Sessions of the European Society for Paediatric Endocrinology GlobeNewswire
Sep-06-18 08:00AM  Soleno Therapeutics Announces Expansion of Ongoing Phase III Trial of DCCR in Prader-Willi Syndrome to Include Younger Patients GlobeNewswire
Sep-04-18 08:00AM  Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Low Lean Body Mass in Prader-Willi Syndrome GlobeNewswire
Aug-14-18 04:05PM  Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results GlobeNewswire
Jul-30-18 08:00AM  Soleno Therapeutics Receives Fast Track Designation from FDA for DCCR for Treatment of Prader-Willi Syndrome GlobeNewswire +8.66%
Jun-04-18 08:00AM  Soleno Therapeutics To Present Corporate Update at the BIO International Convention GlobeNewswire
May-16-18 08:00AM  Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results GlobeNewswire
May-14-18 08:00AM  Soleno Therapeutics Announces Initiation of Phase III Clinical Trial of DCCR in Prader-Willi Syndrome GlobeNewswire +20.25%
Apr-03-18 06:15PM  What Should You Know About Soleno Therapeutics Incs (NASDAQ:SLNO) Future? Simply Wall St.
Apr-02-18 08:00AM  Soleno Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2017 Financial Results GlobeNewswire
Mar-26-18 08:48PM  Does Soleno Therapeutics Incs (NASDAQ:SLNO) Past Performance Indicate A Weaker Future? Simply Wall St.
Mar-16-18 06:14PM  Soleno Therapeutics Inc (NASDAQ:SLNO): Is Breakeven Near? Simply Wall St.
Feb-20-18 08:00AM  Soleno Therapeutics Announces Successful End-of-Phase II Meeting with FDA for DCCR in Prader-Willi Syndrome GlobeNewswire
Dec-12-17 08:30AM  Soleno Therapeutics Announces $15 Million Private Placement GlobeNewswire
Dec-11-17 08:10AM  Todays Research Reports on Stocks to Watch: Soleno Therapeutics and La Jolla Pharmaceutical Company ACCESSWIRE
Dec-08-17 05:43PM  Is Soleno Therapeutics Incs (SLNO) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St. +10.97%
08:00AM  Soleno Therapeutics Announces Joint Venture Agreement for Development and Commercialization of CoSense Monitoring Technology GlobeNewswire
Nov-30-17 03:15PM  Should Soleno Therapeutics Incs (SLNO) Earnings Decline In Recent Times Worry You? Simply Wall St.
Nov-22-17 08:00AM  Soleno Therapeutics to Present at the Piper Jaffray 29th Annual Healthcare Conference GlobeNewswire
Nov-14-17 03:59PM  What Is Soleno Therapeutics Incs (SLNO) Share Price Doing? Simply Wall St. -12.08%
08:00AM  Soleno Therapeutics Provides Corporate Update and Reports Third Quarter 2017 Financial Results GlobeNewswire
Oct-23-17 08:00AM  Soleno Therapeutics Regains Compliance with NASDAQ Listing Requirements GlobeNewswire
Oct-12-17 08:00AM  Soleno Therapeutics Receives Positive Opinion from European Orphan Committee for DCCR in Prader-Willi Syndrome GlobeNewswire
Oct-11-17 08:00AM  Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Hyperphagia in Prader-Willi Syndrome GlobeNewswire +7.98%
Oct-05-17 01:00PM  Soleno Therapeutics Announces 1-for-5 Reverse Stock Split GlobeNewswire -8.46%
Sep-25-17 08:00AM  Soleno Therapeutics Announces Receipt of Scientific Advice from the European Medicines Agency for DCCR in Prader-Willi Syndrome GlobeNewswire
Sep-12-17 03:37PM  Before You Buy Soleno Therapeutics Incs (SLNO), You Should Consider This Simply Wall St.
Aug-24-17 11:22AM  Soleno Therapeutics, Inc. :SLNO-US: Earnings Analysis: Q2, 2017 By the Numbers : August 24, 2017 Capital Cube +12.86%
Soleno Therapeutics, Inc. focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, diazoxide choline controlled-release (DCCR), a tablet for the treatment of Prader-Willi Syndrome (PWS), is entering into late-stage clinical development. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was founded in 1999 and is based in Redwood City, California.
open in yahoo | open in reuters | open in google